OraSure Technologies, Inc. (NASDAQ:OSUR) – Equities research analysts at Jefferies Group lowered their Q2 2018 earnings estimates for shares of OraSure Technologies in a report released on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will post earnings of $0.04 per share for the quarter, down from their prior estimate of $0.09. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for OraSure Technologies’ FY2018 earnings at $0.27 EPS.

Several other analysts have also recently weighed in on OSUR. BidaskClub cut shares of OraSure Technologies from a “strong-buy” rating to a “buy” rating in a report on Thursday. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a report on Friday, February 9th. Canaccord Genuity reiterated a “buy” rating and issued a $24.00 price target on shares of OraSure Technologies in a report on Friday, February 2nd. Finally, ValuEngine cut shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $22.25.

Shares of OraSure Technologies (OSUR) opened at $17.96 on Wednesday. The firm has a market cap of $1,048.00, a price-to-earnings ratio of 35.22, a P/E/G ratio of 4.82 and a beta of 1.43. OraSure Technologies has a fifty-two week low of $10.70 and a fifty-two week high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The company had revenue of $52.00 million for the quarter, compared to the consensus estimate of $50.20 million. During the same period in the previous year, the firm earned $0.13 earnings per share. The firm’s revenue for the quarter was up 46.5% on a year-over-year basis.

Large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in OraSure Technologies by 6.9% in the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock valued at $28,305,000 after acquiring an additional 106,326 shares in the last quarter. USA Financial Portformulas Corp boosted its holdings in OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 13,421 shares in the last quarter. Voya Investment Management LLC boosted its holdings in shares of OraSure Technologies by 179.4% during the 2nd quarter. Voya Investment Management LLC now owns 78,325 shares of the medical instruments supplier’s stock valued at $1,352,000 after buying an additional 50,287 shares in the last quarter. Macquarie Group Ltd. bought a new stake in shares of OraSure Technologies during the 2nd quarter valued at $892,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of OraSure Technologies by 62.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 809,158 shares of the medical instruments supplier’s stock valued at $18,206,000 after buying an additional 311,232 shares in the last quarter. Institutional investors and hedge funds own 91.62% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “OraSure Technologies, Inc. (OSUR) to Post Q2 2018 Earnings of $0.04 Per Share, Jefferies Group Forecasts” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/15/orasure-technologies-inc-osur-to-post-q2-2018-earnings-of-0-04-per-share-jefferies-group-forecasts.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.